Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept (ReSPONSE)

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: October 8, 2009
Last updated: May 14, 2013
Last verified: May 2013

This study proposes to compare 2 different methods for managing a subject with psoriasis who has achieved good disease control, as defined by a clinical response with a Physician Global Assessment (PGA) inferior or equal to 1 at the screening visit, on etanercept treatment.

The first method involves stopping etanercept treatment on entry into the study, with the option to reinitiate etanercept at 50 mg once weekly after medical review and agreement between the subject and the investigator. The second method involves continuing on etanercept at 25 mg once weekly, with the option to increase the dose to 50 mg once weekly after medical review and agreement between the subject and the investigator. Subjects will be randomized into one of these two study arms.

Condition Intervention Phase
Drug: etanercept
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The primary efficacy endpoint is the average 52-week Physician Global Assessment (PGA) measured as the time normalized area under curve. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time-normalized area under the Dermatology Life Quality Index (DLQI) versus time curve. [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Patient satisfaction with Psoriasis treatment at baseline, before retreatment with etanercept 50 mg weekly, and at the end of retreatment [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Mean Physician Global Assessment (PGA) at week 52 [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 176
Study Start Date: January 2010
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Arm 1
Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
Drug: etanercept
etanercept 50 mg once weekly as requested.
Arm 2
Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
Drug: etanercept
etanercept 25 mg or 50 mg as requested.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eighteen (18) years of age or older at the time of consent.
  • Previously treated with etanercept for chronic plaque psoriasis for at least 12 weeks prior to the screening visit and received a total weekly dose of 50 mg per week for at least the 6 weeks preceding the day of the screening visit
  • Having shown clinical response with a PGA inferior or equal to 1 at the screening visit.
  • PGA inferior or equal to 1 at the baseline visit.

Exclusion Criteria:

  • Evidence of skin conditions (eg, eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
  • Evidence of active or previously known medical history of inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis).
  • Any biologics other than etanercept within the 20 weeks prior to the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00992394

  Hide Study Locations
Pfizer Investigational Site
Besancon, France, 25030
Pfizer Investigational Site
Limoges, France, 87042
Pfizer Investigational Site
Lyon Cedex 03, France, 69437
Pfizer Investigational Site
Nantes Cedex 01, France, 44093
Pfizer Investigational Site
Nice Cedex 03, France, 06202
Pfizer Investigational Site
Paris, France, 75010
Pfizer Investigational Site
Pierre Benite, France, 69495
Pfizer Investigational Site
Poitiers, France, 86000
Pfizer Investigational Site
Reims, France, 51100
Pfizer Investigational Site
Toulouse Cedex, France, 31059
Pfizer Investigational Site
Berlin, Germany, 10117
Pfizer Investigational Site
Bochum, Germany, 44791
Pfizer Investigational Site
Erlangen, Germany, 91054
Pfizer Investigational Site
Frankfurt am Main, Germany, 60590
Pfizer Investigational Site
Freiburg, Germany, 79104
Pfizer Investigational Site
Hamburg, Germany, 20246
Pfizer Investigational Site
Osnabrueck, Germany, 49078
Pfizer Investigational Site
Athens, Greece, 16121
Pfizer Investigational Site
Thessaloniki, Greece, 56429
Pfizer Investigational Site
Budapest, Hungary, 1085
Pfizer Investigational Site
Debrecen, Hungary, 4012
Pfizer Investigational Site
Miskolc, Hungary, 3529
Pfizer Investigational Site
Szeged, Hungary, 6720
Pfizer Investigational Site
Catania, Italy, 95123
Pfizer Investigational Site
Chieti, Italy, 66013
Pfizer Investigational Site
Parma, Italy, 43100
Pfizer Investigational Site
Santander, Cantabria, Spain, 39008
Pfizer Investigational Site
Alcorcon, Madrid, Spain, 28922
Pfizer Investigational Site
Getafe, Madrid, Spain, 28905
Pfizer Investigational Site
Alicante, Spain, 3010
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
Malaga, Spain, 29010
Pfizer Investigational Site
Istanbul, Capa, Turkey, 34390
Pfizer Investigational Site
Ankara, Etlik, Turkey, 06010
Pfizer Investigational Site
Istanbul, Fatih, Turkey, 34093
Pfizer Investigational Site
Bursa, Gorukle, Turkey, 16059
Pfizer Investigational Site
Pendik, Istanbul, Turkey, 34890
Pfizer Investigational Site
Ankara, Sihhiye, Turkey, 06100
Pfizer Investigational Site
Bornova / Izmir, Turkey, 35100
United Arab Emirates
Pfizer Investigational Site
Abu Dhabi, UAE, United Arab Emirates, 51900
United Kingdom
Pfizer Investigational Site
Harrogate, United Kingdom, HG2 7SX
Pfizer Investigational Site
London, United Kingdom, E11 1NR
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT00992394     History of Changes
Other Study ID Numbers: 0881X1-4535, B1801021
Study First Received: October 8, 2009
Last Updated: May 14, 2013
Health Authority: European Union: European Medicines Agency

Keywords provided by Pfizer:
Plaque psoriasis - etanercept - response maintenance

Additional relevant MeSH terms:
Skin Diseases
Skin Diseases, Papulosquamous
Immunoglobulin G
TNFR-Fc fusion protein
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014